Radiopharmaceuticals: When and how to use them to treat metastatic bone pain

Fabio M. Paes, Vinicius Ernani, Peter Hosein, Aldo N. Serafini

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Bone pain due to skeletal metastases constitutes the most common type of cancer-related pain. The management of bone pain remains challenging and is not standardized. In patients with multifocal osteoblastic metastases, systemic radiopharmaceuticals should be the preferred adjunctive therapy for pain palliation. The lack of general knowledge about radiopharmaceuticals, their clinical utility and safety profiles, constitutes the major cause for their underutilization. Our goal is to review the indications, selection criteria, efficacy, and toxicities of two approved radiopharmaceuticals for bone pain palliation: strontium-89 and samarium-153. Finally, a brief review of the data on combination therapy with bisphosphonates or chemotherapy is included.

Original languageEnglish (US)
Pages (from-to)197-205
Number of pages9
JournalJournal of Supportive Oncology
Volume9
Issue number6
DOIs
StatePublished - Nov 1 2011

Fingerprint

Radiopharmaceuticals
Bone and Bones
Pain
Samarium
Neoplasm Metastasis
Strontium
Diphosphonates
Pain Management
Patient Selection
Safety
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Radiopharmaceuticals : When and how to use them to treat metastatic bone pain. / Paes, Fabio M.; Ernani, Vinicius; Hosein, Peter; Serafini, Aldo N.

In: Journal of Supportive Oncology, Vol. 9, No. 6, 01.11.2011, p. 197-205.

Research output: Contribution to journalReview article

Paes, Fabio M. ; Ernani, Vinicius ; Hosein, Peter ; Serafini, Aldo N. / Radiopharmaceuticals : When and how to use them to treat metastatic bone pain. In: Journal of Supportive Oncology. 2011 ; Vol. 9, No. 6. pp. 197-205.
@article{370864985bd244e8b033d7d0aa415165,
title = "Radiopharmaceuticals: When and how to use them to treat metastatic bone pain",
abstract = "Bone pain due to skeletal metastases constitutes the most common type of cancer-related pain. The management of bone pain remains challenging and is not standardized. In patients with multifocal osteoblastic metastases, systemic radiopharmaceuticals should be the preferred adjunctive therapy for pain palliation. The lack of general knowledge about radiopharmaceuticals, their clinical utility and safety profiles, constitutes the major cause for their underutilization. Our goal is to review the indications, selection criteria, efficacy, and toxicities of two approved radiopharmaceuticals for bone pain palliation: strontium-89 and samarium-153. Finally, a brief review of the data on combination therapy with bisphosphonates or chemotherapy is included.",
author = "Paes, {Fabio M.} and Vinicius Ernani and Peter Hosein and Serafini, {Aldo N.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.suponc.2011.06.004",
language = "English (US)",
volume = "9",
pages = "197--205",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "6",

}

TY - JOUR

T1 - Radiopharmaceuticals

T2 - When and how to use them to treat metastatic bone pain

AU - Paes, Fabio M.

AU - Ernani, Vinicius

AU - Hosein, Peter

AU - Serafini, Aldo N.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Bone pain due to skeletal metastases constitutes the most common type of cancer-related pain. The management of bone pain remains challenging and is not standardized. In patients with multifocal osteoblastic metastases, systemic radiopharmaceuticals should be the preferred adjunctive therapy for pain palliation. The lack of general knowledge about radiopharmaceuticals, their clinical utility and safety profiles, constitutes the major cause for their underutilization. Our goal is to review the indications, selection criteria, efficacy, and toxicities of two approved radiopharmaceuticals for bone pain palliation: strontium-89 and samarium-153. Finally, a brief review of the data on combination therapy with bisphosphonates or chemotherapy is included.

AB - Bone pain due to skeletal metastases constitutes the most common type of cancer-related pain. The management of bone pain remains challenging and is not standardized. In patients with multifocal osteoblastic metastases, systemic radiopharmaceuticals should be the preferred adjunctive therapy for pain palliation. The lack of general knowledge about radiopharmaceuticals, their clinical utility and safety profiles, constitutes the major cause for their underutilization. Our goal is to review the indications, selection criteria, efficacy, and toxicities of two approved radiopharmaceuticals for bone pain palliation: strontium-89 and samarium-153. Finally, a brief review of the data on combination therapy with bisphosphonates or chemotherapy is included.

UR - http://www.scopus.com/inward/record.url?scp=83455244321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455244321&partnerID=8YFLogxK

U2 - 10.1016/j.suponc.2011.06.004

DO - 10.1016/j.suponc.2011.06.004

M3 - Review article

C2 - 22055888

AN - SCOPUS:83455244321

VL - 9

SP - 197

EP - 205

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 6

ER -